Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT) to a strong-buy rating in a report issued on Thursday,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. Bank of America lowered their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Cantor Fitzgerald increased their target price on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday. Morgan Stanley set a $5.00 price objective on shares of Rocket Pharmaceuticals in a research report on Thursday, January 8th. TD Cowen raised shares of Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Finally, Wedbush restated an “outperform” rating and issued a $16.00 price objective on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $14.50.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKT opened at $5.01 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.30 and a current ratio of 7.30. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $9.73. The business’s 50-day simple moving average is $3.62 and its 200-day simple moving average is $3.45. The firm has a market cap of $542.18 million, a price-to-earnings ratio of -2.49 and a beta of 0.48.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same quarter last year, the firm posted ($0.62) EPS. As a group, equities research analysts expect that Rocket Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.

Insider Transactions at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 12,279 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the sale, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. This represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Martin Wilson sold 12,253 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the sale, the general counsel owned 683,376 shares in the company, valued at approximately $2,261,974.56. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 29,415 shares of company stock worth $97,398 over the last 90 days. 24.76% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in Rocket Pharmaceuticals by 36.9% in the fourth quarter. Invesco Ltd. now owns 304,437 shares of the biotechnology company’s stock worth $1,069,000 after buying an additional 81,984 shares in the last quarter. Corient Private Wealth LLC purchased a new position in Rocket Pharmaceuticals during the 4th quarter valued at about $98,000. Virtus Investment Advisers LLC raised its holdings in shares of Rocket Pharmaceuticals by 111.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 78,474 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 41,410 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Rocket Pharmaceuticals during the 4th quarter valued at about $3,352,000. Finally, Engineers Gate Manager LP grew its holdings in shares of Rocket Pharmaceuticals by 34.5% during the 4th quarter. Engineers Gate Manager LP now owns 96,009 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 24,603 shares during the period. Institutional investors own 98.39% of the company’s stock.

Key Stories Impacting Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded RCKT to a “Strong-Buy” and issued a less-negative FY2026 EPS forecast of ($1.81) vs. the street consensus of ($2.83) — a sign analysts see smaller losses ahead and potential upside if pipeline progress continues. Lifesci upgrade & estimates
• Positive Sentiment: Cantor Fitzgerald raised its price target from $8 to $10 and reiterated an “Overweight” rating, implying substantial upside vs. the current share price and adding buying pressure from growth-focused investors. Cantor Fitzgerald raises PT to $10
• Positive Sentiment: Rocket reported a narrower-than-expected Q4 loss and provided pipeline updates — results that reduce near-term execution risk and keep focus on clinical catalysts that could drive future value. Q4 results & pipeline update
• Neutral Sentiment: Wall Street Zen moved its rating to “Hold,” signaling some caution remains among analysts despite recent positive notes. Wall Street Zen rating change
• Neutral Sentiment: Consensus analyst coverage still averages out to a “Hold,” so while a subset of firms are bullish, broad-market conviction is not unanimous. Analyst consensus summary

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.